Diatide NeoTect Future Indications Will Be Evaluated Off-Label
This article was originally published in The Gray Sheet
Executive Summary
Diatide says that a $2 mil. milestone payment from marketing partner Nycomed Amersham triggered by FDA's Aug. 3 approval of NeoTect will be used in part to bolster its own marketing efforts for the lung cancer imaging agent.